CODEXIS' Q1 2014 RESULTS IMPROVE DESPITE WEAKER SALES

摘要

Codexis Inc.'s total revenue in the first quarter of 2014, ended March 31, fell to $7.07 mln from $11.48 mln a year earlier. The decrease was primarily due to an expected loss of biocatalyst and intermediate sales in the hepatitis C drug marketplace, as a result of both unfavourable market pricing and newer products entering the market, along with a one-time enzyme inventory sale of $2.1 mln to Arch PharmaLabs Ltd. recorded in the first quarter of 2013.